Drugs giant Pfizer has been fined a record £84.2m by the
UK's competition watchdog for overcharging the NHS for an anti-epilepsy drug, Epanutin
(phenytoin sodium).
The Competition and Markets Authority (CMA) also fined
distributor Flynn Pharma £5.2m for the 2,600% price increase for the drug in
2012.
NHS spending on the capsules, used by 48,000 UK patients,
rose from £2m a year in 2012 to about £50m in 2013. UK prices for the drug were
many times higher than in Europe.
No comments:
Post a Comment